Objective To investigate the clinical characteristics and evaluate photodynamic therapy treatment combined with intravitreal injection of Lucentis for choroidal neovascularization secondary to angioid streaks. Methods This was an interventional retrospective analysis of 21 patients （42 eyes）. For clinical data， best corrected visual acuity （BCVA）， fundus appearance， fundus fluorescence angiography （FFA）， indocyanine green angiography （ICGA） and optical coherence tomography （OCT） were assessed. Twenty-two eyes of 18 patients with macular choroidal neovascularizaiton （CNV） were treated first with photodynamic therapy （PDT） and then with an intravitreal injection of Lucentis. The patients were followed up for at least 12 months. Another injection was given if one of the following appeared： decreased visual acuity， new macular lesions， subretinal or intraretinal fluid， or CNV leakage. Data were analyzed using an independent-samples t test or a paired-samples t test. Results Both eyes of all 21 patients were involved. Only 5 patients （24%） had complications with hologathy. Males were more affected （76%）. Of all the patients， 18 cases （86%） were diagnosed with CNV secondary to AS. BCVA was much worse in eyes with CNV. At the final follow-up after the combination treatment， BCVA had improved 10.4 characters. OCT showed macular retinal thickness decreased from 338.4±55.2 μm at baseline to 212.6±36.2 μm. FFA（ICGA） showed CNV leakage in 15 eyes （68%） had disappeared completely， and 5 eyes had scar staining. All patients received 1 treatment of PDT and a mean 3.2 intravitreal injections. Macular subretinal hemorrhage presented in 1 patient after PDT， but was absorbed completely after intravitreal injection. Five patients presented with transient elevated intraocular pressure and 4 patients had subconjunctival hemorrhage but all recovered quickly. No other ocular or adverse reactions occurred. Conclusion Angioid streaks present a special fundus appearance， and FFA（ICGA） is valuable in the diagnosis. A considerable propo
Nakagawa S， Yamashiro K， Tsujikawa A， et al. The time course changes of choroidal neovascularization in angioid streaks[J]. Retina，2013，33（4）：825-833.
[2]
Browning AC， Chung AK， Ghanchi F， et al. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks： one-year results of a prospective case series[J]. Ophthalmology，2005，112（7）：1227-1231.
[3]
Arias L， Pujol O， Rubio M， et al. Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks[J]. Graefes Arch Clin Exp Ophthalmol，2006，244（6）：753-757.
[4]
Lommatzsch A， Spital G， Trieschmann M， et al. Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks[J]. Ophthalmologe， 2007，104（4）：325-328.
[5]
Ladas ID， Kotsolis AI， Ladas DS， et al. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks： one-year results of a prospective study[J]. Retina-J Ret Vit Dis，2010，30（8）：1185-1189.
[6]
Verteporfin Roundtable 2000 and 2001 Participants. Guidelines for using verteporfin （visudyne） in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes[J]. Retina，2002，22（1）：6-18.
[7]
张承芬. 眼底病学[M]. 北京：人民卫生出版社，1998：422-423.
[8]
Menchini U， Virgili G， Introini U， et al. Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy[J]. Retina，2004，24（5）：763-771.
[9]
Ladas ID， Georgalas I， Rouvas AA， et al. Photodynamic therapy with verteporfin of choroidal neovascularization in angioid streaks： conventional versus early retreatment[J]. Eur J Ophthalmol， 2005，15（1）：69-73.
[10]
Jurklies B， Bornfeld N， Schilling H，et al. Photodynamic therapy using verteporfin for choroidal neovascularization associated with angioid streaks—long-term effects[J]. Ophthalmic Res，2006，38（4）：209-217.
[11]
Donati MC， Virgili G， Bini A， et al. Intravitreal bevacizumab （Avastin） for choroidal neovascularization in angioid streaks： a case series[J]. Ophthalmologica，2009，223（1）：24-27.
[12]
Finger RP， Charbel Issa P， Schmitz-Valckenberg S， et al. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum[J]. Retina-J Ret Vit Dis，2011，31（7）：1268-1278.
[13]
Artunay O， Yuzbasioglu E， Rasier R， et al. Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks： preliminary clinical results of 12-month follow-up[J]. Retina，2011，31（7）：1279-1286.
[14]
Prabhu VV， Morris RJ， Shah PK， et al. Combination treatment of low fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane secondary to angioid streaks in Paget′s disease-12 month results[J]. Indian J Ophthalmol， 2011，59（4）：306-308.
[15]
Pece A， Russo G， Ricci F， et al. Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks[J]. Clin Ophthalmol，2010，4：525-530.
[16]
Gliem M， Finger RP， Fimmers R， et al. Treatment of choroidal neovascularization due to angioid streaks： a comprehensive review[J]. Retina-J Ret Vit Dis，2013，33（7）：1300-1314.
浙公网安备 33030202001892号